SANTEN PHARMACEUTICAL CO., LTD.

The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.

The Allergy Relieving Eye Drops Market is projected to grow from USD 1.51 billion in 2023 to USD 2.37 billion by 2032, driven by rising allergy prevalence, demand for non-invasive solutions, and advancements in eye drop formulations. Key markets include Canada, France, India, and UAE, with major companies like AbbVie, Johnson & Johnson, and Pfizer leading the industry.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.